Sucralfate: antipeptic, antiulcer activities and antagonism of gastric emptying.
The antiulcerogenic and antipeptic activities of sucralfate (Ulcerlmin), a basic aluminum sucrose sulfate complex, were investigated. In rats, sucralfate inhibited the formation of ulcers induced by pyloric ligation, indometacin and cysteamine. In doses antagonizing forestomach ulcer formation, sucralfate increased the pH of the gastric juice in a dose-related manner. In vitro, at pH 1.9, sucralfate inhibited rat, dog and hog pepsin in a concentration-related manner and also the peptic activity in human gastric juice. Sucralfate may act as an inhibitor of pepsin by precipitating the enzyme or by binding with it reversibly. The antipeptic activity appears to be directly related to the amount of sucralfate in suspension rather than that in solution. In the gastrointestinal tract, the basic nature of sucralfate may enhance the antipeptic activity of the sucralfate molecule. In rats, sucralfate decreases the rate of gastric emptying.
D000535:Aluminum / Q000494:pharmacology*; D000818:Animals; D000897:Anti-Ulcer Agents; D001285:Atropine / Q000494:pharmacology; D004381:Duodenal Ulcer / Q000517:prevention & control; D005746:Gastric Emptying / Q000187:drug effects*; D005750:Gastric Juice / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D010434:Pepsin A / Q000037:antagonists & inhibitors*; D011134:Polysaccharides / Q000494:pharmacology*; D051381:Rats; D013276:Stomach Ulcer / Q000517:prevention & control; D013392:Sucralfate; D013395:Sucrose / Q000031:analogs & derivatives; D013552:Swine
D000897:Anti-Ulcer Agents; D011134:Polysaccharides; D013392:Sucralfate; D013395:Sucrose; D001285:Atropine; D000535:Aluminum; D010434:Pepsin A